Bone Therapeutics SA (BNZPF)

4.2000 0.0000 (0.00%) At close: 11:30AM EDT

Bone Therapeutics SA

Rue Granbonpré 11 - Bâtiment H
Mont-Saint-Guibert 1435
Belgium
32 49 309 73 66
https://www.bonetherapeutics.com

Sector(s): 
Industry: 
Full-time employees: 20

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Miguel Forte M.D., Ph.D.	CEO, MD & Exec. Director	347.75k	N/A	1960
Dr. Anne-Sophie Lebrun Ph.D.	Chief Operations Officer	N/A	N/A	1983
Dr. Anthony Ting Ph.D.	Chief Scientific Officer	N/A	N/A	1963
Gunther De Backer	Head of Corp. Communications & Investor Relations	N/A	N/A	N/A
Valerie Chapelle	Interim HR Director	N/A	N/A	N/A
Dr. Stefanos Theoharis Ph.D.	Chief Bus. Officer	N/A	N/A	1976
Dr. Anne Leselbaum M.D.	Chief Medical Officer	N/A	N/A	1966
Mr. Ching Man Choi	Bus. Devel. Mang.	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase I/IIa clinical trial for the treatment of delayed-union fractures and lumbar spinal fusion; and JTA-004, an intra-articular injectable that is in phase III clinical trial to treat osteoarthritic pain in the knee. Bone Therapeutics SA was incorporated in 2006 and is based in Mont-Saint-Guibert, Belgium.

Corporate governance

Bone Therapeutics SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.